Novo Nordisk files twice in a day

Danish pharma major Novo Nordisk (NOV: N) has announced two updates in a single day on filings to the US Food and Drug Administration (FDA).

Firstly, the company revealed that it had submitted a Biologics License Application (BLA) to the FDA for Mim8 (denecimig), an investigational prophylaxis treatment for people living with hemophilia A with or without inhibitors. 

Mim8 is designed to help the body form blood clots more effectively and, if approved, would offer the flexibility of a treatment with a single-use, prefilled pen injector with dosing options including once-weekly, once-every-two-weeks, or once-a-month.